Applied dna reports second quarter fiscal 2025 financial results

- therapeutic dna production services segment (linearx) revenues up 44% y/y, contributing to a 6% increase in total revenues - - intra-quarter investor conference call and webcast scheduled for  june 3, 2025, at 4:30 pm et - stony brook, ny / access newswire / may 15, 2025 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today reported financial results for its second quarter of fiscal 2025 ended march 31, 2025. the company's form 10-q for its fiscal second quarter can be viewed on the sec filings page of its investor relations website.
APDN Ratings Summary
APDN Quant Ranking